Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Nasus Pharma Ltd. ( (NSRX) ).
Nasus Pharma Ltd., a company involved in the pharmaceutical industry, announced changes in its board of directors on September 3, 2025. Dan Teleman, the Chief Executive Officer, has been appointed as a Class III director, filling a vacancy on the board. His term will last until the annual general meeting of shareholders in 2028. Additionally, the board has replaced David Silberman with Ronnie Hershman on the Compensation Committee, indicating a strategic shift in its governance structure.
More about Nasus Pharma Ltd.
Average Trading Volume: 65,486
Find detailed analytics on NSRX stock on TipRanks’ Stock Analysis page.